The aim of this study is to clarify the functional role of NKX3.1 in PCa cells under varying contexts of AR activity, including androgen deprivation, androgen stimulation, and active antagonization in the form of the commonly clinically-utilized AR-antagonist enzalutamide, in both therapy-naïve and therapy-resistant cells [8]. This evidence concerns the gene NKX3-1 and posterior cortical atrophy.